Using data gathered from the National Ambulatory Medical Care Survey, the authors of a JAMA Internal Medicine study identified a significant decrease in PSA testing referrals by primary care physicians compared with urologists.
Declines in prostate-specific antigen (PSA) testing differed among urologist and primary care physician visits in a study that compared testing before and after a 2011 recommendation from the US Preventive Services Task Force against PSA screening for all men, according to an article published online by JAMA Internal Medicine.
The authors gathered data from the National Ambulatory Medical Care Survey to examine continued adoption of PSA testing before (2010) and after (2012) the USPSTF recommendation. The survey, write the authors, collects information on outpatient physician visits, patient demographics, diagnoses, medications, and indications for consulting. The authors included all visits for men (ages 50 to 74 years) who went to urologists or primary care physicians (PCPs) for a preventive care visit. After excluding men with a diagnosis of prostate cancer and other conditions of the prostate, the study sample included 1164 visits (representing 27 million eligible visits) in 2010 and 2012, of which 64 visits (representing 800,000 visits) were provided by urologists and 1100 visits (representing 26.2 million visits) were by PCPs.
Use of PSA testing decreased from 36.5% in 2010 to 16.4% in 2012 among PCP visits (odds ratio [OR], 0.43; 95% CI, 0.23-0.81; P = .009) and from 38.7% in 2010 to 34.5% in 2012 among urologist visits (OR, 0.34; 95% CI, 0.10-1.20; P = .09), the authors discovered.
The authors explain that the difference in decline may either reflect differing perceptions among physicians on the benefit of PSA screening, conflicting guidelines (the American Urological Association recommends joint decision making for men 55 to 69 years), or possibly patient demographics or expectations.
Important study limitations to note include relying on records of outpatient clinic visits and not accounting for PSA testing outside of physician outpatient visits. Also, the authors used the order of a PSA test as a surrogate for an actual test being performed, which may not necessarily be accurate.
“Moving forward, this finding emphasizes the need to continue interdisciplinary dialogue to achieve a broader consensus on prostate cancer screening,” the authors conclude.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More